Marinus Pharmaceuticals (NASDAQ: MRNS) is one of 112 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Marinus Pharmaceuticals to similar businesses based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Insider and Institutional Ownership

28.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.4% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Marinus Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals’ peers have a beta of 0.86, meaning that their average share price is 14% less volatile than the S&P 500.

Profitability

This table compares Marinus Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marinus Pharmaceuticals N/A -107.40% -75.54%
Marinus Pharmaceuticals Competitors -3,615.35% -50.25% -8.94%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Marinus Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marinus Pharmaceuticals 0 0 2 0 3.00
Marinus Pharmaceuticals Competitors 940 3771 5984 164 2.49

Marinus Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 70.73%. As a group, “Pharmaceuticals” companies have a potential upside of 25.98%. Given Marinus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than its peers.

Valuation and Earnings

This table compares Marinus Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Marinus Pharmaceuticals N/A -$22.16 million -3.69
Marinus Pharmaceuticals Competitors $7.86 billion $2.50 billion 0.98

Marinus Pharmaceuticals’ peers have higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Marinus Pharmaceuticals peers beat Marinus Pharmaceuticals on 7 of the 12 factors compared.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.